Meeting
2022 ASCO Annual Meeting
Post-recurrence survival in asymptomatic compared with symptomatic metastatic breast cancer: A multicenter retrospective study.
Authors
Sayaka Kuba
Nagasaki University Graduate school of biomedical Science, Nagasaki, Japan
Sayaka Kuba , Shigeto Maeda , Shigeki Minami , Hiroki Moriuchi , Aya Tanaka , Momoko Akashi , Michi Morita , Chika Sakimura , Masayuki Baba , Ryota Otsubo , Megumi Matsumoto , Kosho Yamanouchi , Hiroshi Yano , Kengo Kanetaka , Takeshi Nagayasu , Susumu Eguchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1049)
DOI
10.1200/JCO.2022.40.16_suppl.1049
Abstract #
1049
Poster Bd #
427
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
First Author: Binghe Xu
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.
First Author: Sara M. Tolaney
Poster
2020 ASCO Virtual Scientific Program
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer.
First Author: Matthew Loft
Poster
2019 ASCO Annual Meeting
Everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer patients previously treated with CDK4/6 inhibitor based therapies.
First Author: Madeline Cook